Jae Won Lee

S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial

D. Shin, Tae Won Kim, Keun-Wook Lee, 2014, BMC Cancer.

S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial.

D. Shin, Tae Won Kim, Keun-Wook Lee, 2012, The Lancet. Oncology.

Whole blood Epstein-Barr virus DNA load as a diagnostic and prognostic surrogate: extranodal natural killer/T-cell lymphoma

C. Ki, Hyo Song Kim, Kihyun Kim, 2009, Leukemia & lymphoma.

First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung.

Hyae-Young Kim, J. Ahn, M. Ahn, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prediction of Recurrence-Free Survival in Postoperative Non–Small Cell Lung Cancer Patients by Using an Integrated Model of Clinical Information and Gene Expression

Nam Huh, Kyusang Lee, Yong Soo Choi, 2008, Clinical Cancer Research.

Gefitinib versus pemetrexed as second‐line treatment in patients with nonsmall cell lung cancer previously treated with platinum‐based chemotherapy (KCSG‐LU08‐01)

J. Ahn, M. Ahn, Keunchil Park, 2012, Cancer.

Korean red ginseng for cancer-related fatigue in colorectal cancer patients with chemotherapy: A randomised phase III trial.

Myung Ah Lee, D. Shin, S. Oh, 2020, European journal of cancer.